BridgeBio Pharma, Inc. Updates
BridgeBio Pharma, Inc. (NASDAQ: BBIO) announced significant developments in its ATTR‑CM therapy portfolio on September 23, 2026. The biotechnology company, which focuses on medications for genetic diseases, reported that its lead product, Acoramidis, demonstrated a real‑world benefit versus the existing treatment tafamidis in patients with transthyretin amyloid cardiomyopathy (ATTR‑CM). The study showed a reduction in the risk of clinical worsening, positioning Acoramidis as a potentially more effective therapeutic option for this condition.
In a separate release from the same day, BridgeBio stated that its heart‑disease therapy Attruby outperformed Pfizer’s Vyndamax in a real‑world study. This comparison underscores the company’s competitive stance in the ATTR‑CM therapeutic arena.
Shareholder Activity
On September 21, 2026, BridgeBio’s chief executive officer, Neil Kumar, sold shares worth $690,847. This transaction, disclosed through an official filing, reflects personal divestment activity by the CEO.
Company Context
- Market Capitalization: $13.05 billion (USD)
- Recent Share Price: $69.23 (close on 2026‑09‑21)
- 52‑Week Range: $48.78 – $93.42
- Price‑to‑Earnings Ratio: –18.67 (negative, indicating losses)
- Sector: Health Care (Biotechnology)
- Primary Exchange: Nasdaq
- Headquarters: Palo Alto, United States
BridgeBio Pharma continues to develop therapies targeting genetic disorders, with a global patient focus. For more information, the company’s website is www.bridgebio.com .
